Business Wire

Shippeo Announces Anand Medepalli as Chief Product Officer

14.12.2021 11:00:00 EET | Business Wire | Press release

Share

Shippeo, a global leader and European specialist in real-time transportation visibility, has announced the appointment of Anand Medepalli as their Chief Product Officer to lead the company during a time of immense growth and support clients with an innovative vision of Shippeo’s product offering.

Anand has over 25 years of experience as a trusted advisor with leading companies in product strategies, commercial account strategies, and asset planning decisions in transportation, supply chain, and financial services. He has spent much of his career advising companies and defining innovative solutions to drive their growth. Before Shippeo, Anand was Head of AI Solutions at ServiceNow, following the acquisition of Element AI, where he was Head of Products. Previous to this experience, Anand worked for several years at Blue Yonder, as the VP of Retail Planning products.

"One look around and you know that supply chains are under stress. Shippers, carriers, and LSPs need unprecedented visibility into their supply chains to serve their customers, and they need solutions that give them accurate insights into their operations,” says newly appointed Chief Product Officer, Anand Medepalli. “Shippeo, with its right vision and impressive technology, is addressing this problem head-on for some very innovative and well-known customers, and delivering significant value to them. It was a no-brainer for me to join the talented Shippians as I understood that this was where I could indulge in my passion for supply chain, big data, machine learning and AI in one place and at the same time make a significant positive difference to our customers."

With over 100 customers, including global brands like Coca-Cola HBC, Faurecia, and Total, Shippeo offers a best-in-market ETA prediction in terms of accuracy and reliability as well as a more granular degree of multimodal tracking, right down to handling unit and goods levels, which supports all modes of transport including ocean, road, LTL and FTL. Shippeo's ambition is to be the leading supply chain operating system, enabling fully automated and sustainable supply chains across the world.

Lucien Besse, Shippeo’s Chief Operating Officer, welcomes Anand to the team. “We are thrilled to welcome Anand to the Shippeo executive leadership team. He brings great skills at the intersection of product strategy, AI, machine learning, and supply chain management to the company”, said Besse. “As the Chief Product Officer, he will set the product strategy to disrupt the supply chain visibility marketplace with innovative solutions, playing a key role in the company’s development and continued success. His intimate knowledge and experience within the market are invaluable, and he will no doubt be a great asset within our leadership team.”

More information

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Celine Bonniot, Field Marketing Director, Shippeo, celine.bonniot@shippeo.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Safe Software to Increase Global Headcount by Over 15% as Demand for AI-Ready Data Grows2.9.2026 16:00:00 EEST | Press release

Safe Software, the creator of FME, the only All-Data, Any-AI enterprise integration platform with true support for spatial data, today announced it is recruiting for more than 60 roles throughout the remainder of 2026. The hiring will take the company past 400 employees, increasing headcount by over 15%, with new positions across the United Kingdom, the United States and Canada. The expansion follows a year in which Safe crossed $100 million in annual revenue, growing close to 20 percent year over year and moving ahead of schedule on its target of $250 million by 2028. The company also grew its employee base by over 20% in the same period. "The incredible growth that we’ve seen over the last 30+ years at Safe has always been a testament to the great people behind what we do," said Don Murray, Co-Founder and CEO of Safe Software. "Almost every organization we speak to is trying to get its data ready for AI, and most of them are realizing that the hard part is not the model, it is the da

Egon Zehnder Names Ayşe Güçlü Onur Global Human Resources Practice Leader2.9.2026 16:00:00 EEST | Press release

Egon Zehnder has appointed Ayşe Güçlü Onur as Global Leader of its Human Resources Practice. This appointment comes as companies and boards increasingly look to CHROs to help shape business strategy, lead transformation, build leadership pipelines, and navigate major shifts in culture and the workforce. "CHROs used to be evaluated by how well they supported the business. Today, the best drive it," said Onur. "Our role is to help CHROs move from a seat at the table to a hand in business growth. We help them connect leadership decisions, talent, and culture directly to elevated performance. That's the shift Egon Zehnder is built to guide with our leadership advisory services." Egon Zehnder’s Human Resources Practice partners with companies to discover, develop, and transform future-ready CHROs, helping them shape the future of the function. This includes executive search, leadership assessment and development, board effectiveness, culture, succession planning, organizational transformati

Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Data to Boehringer Ingelheim2.9.2026 15:00:00 EEST | Press release

Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together with multimodal patient data, aiming to speed up the discovery process across multiple indications in oncology and immunology. This agreement builds upon an initial pilot undertaken by Owkin with Boehringer in 2025. In that pilot Owkin delivered deep spatial insights into the tumor microenvironment of a gene target through its MOSAIC dataset. Under the new agreement, Owkin will license multimodal oncology data to Boehringer and will generate new multimodal data in immunology. Owkin licenses, sources and generates multimodal patient data in collaboration with its global patient data network. Boehringer Ingelheim’s teams will access and analyze this data through K Pro, which provides a single environment to interrogate data and run reproducible analyses. K Pro’s reasoning capabilities supp

Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience2.9.2026 15:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) for a fully human VHH antibody molecule. Under the agreement, Biocytogen will grant Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody molecule to support its research and development of innovative therapeutics in the neuroscience field. The licensed VHH antibody molecule was generated from Biocytogen’s proprietary RenNano® platform. The RenNano® platform is designed to discover fully human VHH antibody molecules with favorable specificity, binding affinity, and developability, and can generate molecular building blocks for the design and development of VHH antibodies, bispecific/multispecific antibodies, antibody-drug conjugates, and other innovative modalities. Through this license, Qilu Pharmaceutical may advance the research and development o

Croma-Pharma Introduces Electronic Instructions for Use Across the saypha ® Portfolio2.9.2026 14:37:00 EEST | Press release

Croma-Pharma has introduced electronic Instructions for Use (eIFU) across its saypha® portfolio in markets where applicable regulations permit electronic Instructions for Use to replace printed versions. The transition expands digital access to essential product information for healthcare professionals while reducing the use of printed documentation. Healthcare professionals can access the current approved Instructions for Use by scanning the QR code on the saypha® folding box. The eIFU platform provides direct digital access to the latest approved Instructions for Use. "Innovation extends beyond product development. It also includes how we provide healthcare professionals with access to essential product information," said Andreas Prinz, Chief Executive Officer of Croma-Pharma. "The introduction of electronic Instructions for Use across the saypha® portfolio reflects our focus on practical digital solutions that support healthcare professionals and align with evolving regulatory requi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye